Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 9/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15046120 | 0.81 | LRRK2 (0.50) | ULK1 | |
| SCHEMBL173502 | 0.77 | NAMPT (0.46) | ULK1NAMPTKDM4ESTAT3HIF1A | |
| SCHEMBL176794 | 0.74 | MAPK1 (0.46) | NAMPT | |
| SCHEMBL18197033 | 0.71 | MAP2K1 (0.36) | ULK1 | |
| SCHEMBL17728948 | 0.69 | RAB9A (0.48) | — | |
| SCHEMBL18197001 | 0.68 | MAP2K1 (0.33) | ULK1NAMPT | |
| SCHEMBL4793050 | 0.68 | KDM4E (0.65) | NAMPTKDM4ESTAT3HIF1AFLT3 | |
| SCHEMBL173308 | 0.68 | KDM4E (0.65) | ULK1NAMPTKDM4ESTAT3HIF1A | |
| SCHEMBL13245137 | 0.67 | KDM4E (0.60) | NAMPTKDM4ESTAT3HIF1ANTRK1 | |
| SCHEMBL4291226 | 0.67 | KDM4E (0.63) | NAMPTKDM4ESTAT3HIF1AFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2613782-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946216-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| WO-2012030685-A2 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158020-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MAPK3, MAPK1, MAP3K1 | ULK1 303/4885NAMPT 1686/4885KDM4E 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.